Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. (NASDAQ: COSM) generates a steady flow of news across pharmaceuticals, nutraceuticals, healthcare services and digital assets, reflecting its description as a diversified, vertically integrated global healthcare group. News coverage often highlights developments in its proprietary brands, EU-based manufacturing operations, distribution activities, research and development programs, telehealth initiatives and financing arrangements.
Recent press releases have focused on record quarterly financial results, including revenue growth and margin expansion attributed to contract manufacturing at Cana Laboratories, UK distribution through Decahedron, the CosmoFarm distribution business, and global expansion of brands such as Sky Premium Life and C-Sept/C-Scrub. Coverage has also included manufacturing agreements, such as the PathMuscle production agreement through Cana Laboratories, which illustrates the company’s role as a pharmaceutical manufacturing partner.
Investors following COSM news will also see updates on Cosmos Health’s R&D pipeline, including programs like CCX0722 for obesity and weight management and other repurposed compounds targeting major disorders. News items describe how these efforts are supported by the Cloudscreen AI-enabled drug repurposing platform and by initiatives in nanotechnology to develop next-generation nutraceutical formulas.
Beyond core healthcare operations, Cosmos Health issues news about its digital asset strategy, including Ethereum purchases under a $300 million facility and a strategic partnership with Prime Ledger LLC to manage digital asset treasury operations and tokenize intellectual property. Regulatory and capital markets updates, such as Nasdaq listing compliance notices, financing transactions involving senior secured convertible notes, and shareholder meeting outcomes, also feature prominently.
For readers tracking COSM, this news stream provides insight into how the company is executing across manufacturing, distribution, R&D, telehealth and digital finance. Regular updates help contextualize financial performance, strategic partnerships and regulatory milestones that shape Cosmos Health’s trajectory.
Cosmos Health (NASDAQ:COSM) announced on March 11, 2026 the purchase of $600,000 of Bitcoin, raising its total digital asset holdings to $3.1 million across Bitcoin and Ethereum. The company described the buys as part of a disciplined treasury strategy to diversify the balance sheet and maintain financial flexibility.
Management said these digital assets may be monetized if needed to address a discount to book value and to support shareholder-value initiatives.
Cosmos Health (NASDAQ:COSM) entered a 90-day LOI dated March 6, 2026 to acquire a pharmacy distribution network that currently generates approximately €10 million (≈$11.5 million) in annual gross revenue. The network serves broad pharmacy customers in Greece and would integrate with CosmoFarm’s automated logistics to drive efficiencies. The acquisition remains subject to a definitive agreement and customary closing conditions and is presented as part of Cosmos Health’s strategy to help achieve its 2027 revenue guidance of $155.8 million through organic growth and disciplined acquisitions.
Cosmos Health (NASDAQ:COSM) appointed Dr. Dimitrios Iliopoulos to its Advisory Board on February 24, 2026 to support AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos brings academic, biotech leadership, and AI platform experience, including a Phase 2 AI-derived small molecule program.
Cosmos Health (NASDAQ:COSM) highlighted an estimated $15 million fair market value for its wholly owned real estate portfolio in Athens, exceeding its $13.5 million market capitalization as of Feb 17, 2026. Management is evaluating monetization options — sale, JV, or sale-leaseback — to unlock shareholder value.
The two properties are unencumbered, located in Neo Iraklio and Peristeri, and exclude machinery and equipment from the valuation.
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now available through Superdrug in the UK as of Feb 18, 2026. Superdrug operates more than 830 stores and a strong online platform, including over 200 in-store pharmacies.
This listing expands C-Scrub’s retail and pharmacy reach in the UK and Ireland, increasing brand exposure across broad-based and health-focused consumer channels and supporting regional product development plans.
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now carried by Tesco, the UK’s largest retailer. This expands C-Scrub’s UK retail footprint, increasing visibility and accessibility via Tesco’s nationwide stores and online platform, and supports future portfolio rollout in Europe.
Cosmos Health (NASDAQ:COSM) exhibited at World Health Expo Dubai 2026 (Feb 9–12) to showcase its expanding portfolio of proprietary nutraceutical and wellness brands, including Sky Premium Life, NOOR, C-Scrub, and Mediterranation.
The company highlighted vertical manufacturing, expanded distribution in Europe, Middle East and North America, and ongoing discussions with potential partners across Asia and Latin America.
Cosmos Health (NASDAQ:COSM) expanded its digital assets program by purchasing $500,000 of Bitcoin, bringing total cryptocurrency investments to $2.5 million. Ethereum remains a key pillar while the company will selectively evaluate other cryptocurrencies based on market conditions and strategic fit.
The purchase was executed at an average price below $70,000 per Bitcoin, reflecting a disciplined, opportunistic capital deployment approach aligned with long-term financial objectives.
Cosmos Health (NASDAQ:COSM) reported continued operational growth at Cosmofarm in 2025, adding nearly 100 new pharmacy customers (about a 20% weighted increase in active customer base). The business saw annual revenue per customer +12% and profitability per customer +14%, driven by improved route density, order execution and operational leverage. Cosmofarm added three new delivery routes in Attica and is upgrading a 29,000-square-foot Athens facility with expanded distribution and temperature-controlled storage. The company continues multi-year investments in ROWA and A-frame robotic systems and is executing an additional ~$1 million capital program to expand robotic capacity, supporting an incremental annual revenue potential of approximately $40 million as volumes scale.
Cosmos Health (NASDAQ:COSM) announced that Zacks Small-Cap Research initiated coverage on January 13, 2026, assigning a $4.50 per share valuation based on a five-year DCF using a 20% discount rate and a 2% terminal growth rate. Zacks projects revenue growth from $64.4M in 2025 to $98.6M in 2026 and to over $130M in 2027, driven by higher-margin pharmaceuticals, nutraceutical brands, telehealth, and Cloudscreen AI-enabled R&D. The report cites Cosmos Health’s U.S. expansion (ZipDoctor, Sky Premium Life), a disclosed $300M financing facility, ETH purchases, and record Q3 2025 revenue and improved adjusted EBITDA as supporting factors. Cosmos disclosed it paid Zacks for the report.